Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Adrián Mosquera Orgueira"'
Autor:
Yu-Hung Wang, Adrián Mosquera Orgueira, Chien-Chin Lin, Chi-Yuan Yao, Min-Yen Lo, Cheng-Hong Tsai, Adolfo de la Fuente Burguera, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract The European Leukemia Net recommendations provide valuable guidance in treatment decisions of patients with acute myeloid leukemia (AML). However, the genetic complexity and heterogeneity of AML are not fully covered, notwithstanding that ge
Externí odkaz:
https://doaj.org/article/6ead356802e74eccaafc335f241b2a39
Refining risk prediction in pediatric acute lymphoblastic leukemia through DNA methylation profiling
Autor:
Adrián Mosquera Orgueira, Olga Krali, Carlos Pérez Míguez, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Marta Sonia González Pérez, Manuel Mateo Pérez Encinas, Manuel Fernández Sanmartín, Daniel Sinnet, Mats Heyman, Gudmar Lönnerholm, Ulrika Norén-Nyström, Kjeld Schmiegelow, Jessica Nordlund
Publikováno v:
Clinical Epigenetics, Vol 16, Iss 1, Pp 1-13 (2024)
Abstract Acute lymphoblastic leukemia (ALL) is the most prevalent cancer in children, and despite considerable progress in treatment outcomes, relapses still pose significant risks of mortality and long-term complications. To address this challenge,
Externí odkaz:
https://doaj.org/article/524a99df0c2a49bea5b4ae1c671020b2
Publikováno v:
Frontiers in Hematology, Vol 3 (2024)
Multiple myeloma is the second most frequent hematologic malignancy worldwide with high morbidity and mortality. Although it is considered an incurable disease, the enhanced understanding of this neoplasm has led to new treatments, which have improve
Externí odkaz:
https://doaj.org/article/d9f7fa5d4a064944be97b7dc614ca683
Autor:
Davide Crucitti, Carlos Pérez Míguez, José Ángel Díaz Arias, Diego Beltrán Fernandez Prada, Adrián Mosquera Orgueira
Publikováno v:
Frontiers in Hematology, Vol 3 (2024)
Developing new drugs is a complex and formidable challenge, intensified by rapidly evolving global health needs. De novo drug design is a promising strategy to accelerate and refine this process. The recent introduction of Generative Artificial Intel
Externí odkaz:
https://doaj.org/article/f0d2a8df14e14f1a81e5705a2ca897db
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/5b644d52caf6407c83da3785ab40f5bd
Autor:
Adrián Mosquera Orgueira, Jose Ángel Díaz Arías, Rocio Serrano Martín, Victor Portela Piñeiro, Miguel Cid López, Andrés Peleteiro Raíndo, Laura Bao Pérez, Marta Sonia González Pérez, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, Juan Carlos Vallejo Llamas, José Luis Bello López
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short su
Externí odkaz:
https://doaj.org/article/617f5691a8e74047b11c6b9eeaa33179
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Risk stratification in acute myeloid leukemia (AML) has been extensively improved thanks to the incorporation of recurrent cytogenomic alterations into risk stratification guidelines. However, mortality rates among fit patients assigned to low or int
Externí odkaz:
https://doaj.org/article/5aede6c8b7c54ba38df284fa7e1db4fd
Autor:
Adrián Mosquera Orgueira, Marta Sonia González Pérez, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, María-Victoria Mateos
Publikováno v:
HemaSphere, Vol 6, Iss 8, p e760 (2022)
A growing need to evaluate risk-adapted treatments in multiple myeloma (MM) exists. Several clinical and molecular scores have been developed in the last decades, which individually explain some of the variability in the heterogeneous clinical behavi
Externí odkaz:
https://doaj.org/article/4399b4f53e80492b831879dfbbf7ab29
Autor:
Marina Gómez-Llobell, Andrés Peleteiro Raíndo, Jose Climent Medina, Ignacio Gómez Centurión, Adrián Mosquera Orgueira
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundExperience with immune checkpoint inhibitors (ICIs) in the treatment of acute myeloid leukemia (AML) is still limited and based on early clinical trials, with no reported randomized clinical data. In this study, we reviewed the available ev
Externí odkaz:
https://doaj.org/article/07cb54b021d04747aa020b37a948fd52
Autor:
Adrián Mosquera Orgueira, Jose Ángel Díaz Arías, Miguel Cid López, Andrés Peleteiro Raíndo, Alberto López García, Rosanna Abal García, Marta Sonia González Pérez, Beatriz Antelo Rodríguez, Carlos Aliste Santos, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, José Luis Bello López
Publikováno v:
HemaSphere, Vol 6, Iss 4, p e706 (2022)
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Despite notable therapeutic advances in the last decades, 30%–40% of affected patients develop relapsed or refractory disease that frequently precludes an infamo
Externí odkaz:
https://doaj.org/article/4028d800fdc4470ea9215a7e8ef0f9b9